Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.

Rieckmann P, Centonze D, Giovannoni G, Hua LH, Oreja-Guevara C, Selchen D, Sorensen PS, Vermersch P, Wiendl H, Salloukh H, Yamout B (2023)

Publication Type: Journal article, Review article

Publication year: 2023

Journal

Neurodegenerative Disease Management Future Medicine

Book Volume: 13

Pages Range: 5-13

Journal Issue: 1

DOI: 10.2217/nmt-2022-0027

Abstract

WHAT IS THIS SUMMARY ABOUT?: People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets. WHAT WERE THE RESULTS?: The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets. WHAT DO THE RESULTS MEAN?: Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.

Involved external institutions

Medical Park Loipl DE Germany (DE) IRCCS Istituto Neurologico Mediterraneo Neuromed IT Italy (IT) Queen Mary, University of London GB United Kingdom (GB) Cleveland Clinic US United States (USA) (US) Hospital Clínico San Carlos ES Spain (ES) University of Toronto CA Canada (CA) University of Copenhagen DK Denmark (DK) LILLE 1 University - Science and Technology FR France (FR) Harley Street Medical Centre AE United Arab Emirates (AE)

How to cite

APA:

Rieckmann, P., Centonze, D., Giovannoni, G., Hua, L.H., Oreja-Guevara, C., Selchen, D.,... Yamout, B. (2023). Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. Neurodegenerative Disease Management, 13(1), 5-13. https://dx.doi.org/10.2217/nmt-2022-0027

MLA:

Rieckmann, Peter, et al. "Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary." Neurodegenerative Disease Management 13.1 (2023): 5-13.

BibTeX: Download